Literature DB >> 24189494

Bcrp1 transcription in mouse testis is controlled by a promoter upstream of a novel first exon (E1U) regulated by steroidogenic factor-1.

Yi Xie1, Karthika Natarajan, Kenneth S Bauer, Takeo Nakanishi, William T Beck, Rebecca S Moreci, Pancharatnam Jeyasuria, Arif Hussain, Douglas D Ross.   

Abstract

Alternative promoter usage is typically associated with mRNAs with differing first exons that contain or consist entirely of a 5' untranslated region. The murine Bcrp1 (Abcg2) transporter has three alternative promoters associated with mRNAs containing alternative untranslated first exons designated as E1A, E1B, and E1C. The E1B promoter regulates Bcrp1 transcription in mouse intestine. Here, we report the identification and characterization of a novel Bcrp1 promoter and first exon, E1U, located upstream from the other Bcrp1 promoters/first exons, which is the predominant alternative promoter utilized in murine testis. Using in silico analysis we identified a putative steroidogenic factor-1 (SF-1) response element that was unique to the Bcrp1 E1U alternative promoter. Overexpression of SF-1 in murine TM4 Sertoli cells enhanced Bcrp1 E1U mRNA expression and increased Bcrp1 E1U alternative promoter activity in a reporter assay, whereas mutation of the SF-1 binding site totally eliminated Bcrp1 E1U alternative promoter activity. Moreover, expression of Bcrp1 E1U and total mRNA and Bcrp1 protein was markedly diminished in the testes from adult Sertoli cell-specific SF-1 knockout mice, in comparison to the testes from wild-type mice. Binding of SF-1 to the SF-1 response element in the E1U promoter was demonstrated by chromatin immunoprecipitation assays. In conclusion, nuclear transcription factor SF-1 is involved with the regulation of a novel promoter of Bcrp1 that governs transcription of the E1U mRNA isoform in mice. The present study furthers understanding of the complex regulation of Bcrp1 expression in specific tissues of a mammalian model.
© 2013.

Entities:  

Keywords:  5′ UTR; 5′ untranslated region; Breast cancer resistance protein (ABCG2); Mouse; Promoter; SF-1; Steroidogenic factor-1 (SF-1); TSS; Testis; steroidogenic factor-1; transcriptional start site

Mesh:

Substances:

Year:  2013        PMID: 24189494      PMCID: PMC3873745          DOI: 10.1016/j.bbagrm.2013.10.008

Source DB:  PubMed          Journal:  Biochim Biophys Acta        ISSN: 0006-3002


  49 in total

Review 1.  Breast cancer resistance protein (Bcrp) and the testis--an unexpected turn of events.

Authors:  Xiaojing Qian; Yan-Ho Cheng; Dolores D Mruk; C Yan Cheng
Journal:  Asian J Androl       Date:  2013-05-13       Impact factor: 3.285

Review 2.  Role of breast cancer resistance protein (BCRP/ABCG2) in cancer drug resistance.

Authors:  Karthika Natarajan; Yi Xie; Maria R Baer; Douglas D Ross
Journal:  Biochem Pharmacol       Date:  2012-01-11       Impact factor: 5.858

3.  Identification of a novel, tissue-specific ABCG2 promoter expressed in pediatric acute megakaryoblastic leukemia.

Authors:  Patrick K Campbell; Yang Zong; Shengping Yang; Sheng Zhou; Jeffrey E Rubnitz; Brian P Sorrentino
Journal:  Leuk Res       Date:  2011-10       Impact factor: 3.156

Review 4.  Beyond steroidogenesis: novel target genes for SF-1 discovered by genomics.

Authors:  Enzo Lalli; Mabrouka Doghman; Perle Latre de Late; Abeer El Wakil; Isabelle Mus-Veteau
Journal:  Mol Cell Endocrinol       Date:  2012-11-17       Impact factor: 4.102

5.  Identification and characterization of the major alternative promoter regulating Bcrp1/Abcg2 expression in the mouse intestine.

Authors:  Karthika Natarajan; Yi Xie; Takeo Nakanishi; William T Beck; Kenneth S Bauer; Douglas D Ross
Journal:  Biochim Biophys Acta       Date:  2011-06-28

6.  Aryl hydrocarbon receptor is a transcriptional activator of the human breast cancer resistance protein (BCRP/ABCG2).

Authors:  Kah Poh Tan; Bernice Wang; Mingdong Yang; Paul C Boutros; Jane Macaulay; Haibo Xu; Andrew I Chuang; Kazuhiro Kosuge; Mika Yamamoto; Shinichiro Takahashi; Alex M L Wu; Douglas D Ross; Patricia A Harper; Shinya Ito
Journal:  Mol Pharmacol       Date:  2010-05-11       Impact factor: 4.436

7.  Kinetic analysis of the cooperation of P-glycoprotein (P-gp/Abcb1) and breast cancer resistance protein (Bcrp/Abcg2) in limiting the brain and testis penetration of erlotinib, flavopiridol, and mitoxantrone.

Authors:  Hiroshi Kodaira; Hiroyuki Kusuhara; Junko Ushiki; Eiichi Fuse; Yuichi Sugiyama
Journal:  J Pharmacol Exp Ther       Date:  2010-03-19       Impact factor: 4.030

8.  Expression of ATP-binding cassette membrane transporters in rodent and human sertoli cells: relevance to the permeability of antiretroviral therapy at the blood-testis barrier.

Authors:  Kevin R Robillard; Tozammel Hoque; Reina Bendayan
Journal:  J Pharmacol Exp Ther       Date:  2011-10-11       Impact factor: 4.030

9.  Role of breast cancer resistance protein in the bioavailability and fetal penetration of topotecan.

Authors:  J W Jonker; J W Smit; R F Brinkhuis; M Maliepaard; J H Beijnen; J H Schellens; A H Schinkel
Journal:  J Natl Cancer Inst       Date:  2000-10-18       Impact factor: 13.506

10.  Localization of breast cancer resistance protein (Bcrp) in endocrine organs and inhibition of its transport activity by steroid hormones.

Authors:  Anita C A Dankers; Fred C G J Sweep; Jeanne C L M Pertijs; Vivienne Verweij; Jeroen J M W van den Heuvel; Jan B Koenderink; Frans G M Russel; Rosalinde Masereeuw
Journal:  Cell Tissue Res       Date:  2012-05-13       Impact factor: 5.249

View more
  2 in total

1.  Functional cyclic AMP response element in the breast cancer resistance protein (BCRP/ABCG2) promoter modulates epidermal growth factor receptor pathway- or androgen withdrawal-mediated BCRP/ABCG2 transcription in human cancer cells.

Authors:  Yi Xie; Takeo Nakanishi; Karthika Natarajan; Lowell Safren; Anne W Hamburger; Arif Hussain; Douglas D Ross
Journal:  Biochim Biophys Acta       Date:  2015-01-21

2.  Methods to Discover Alternative Promoter Usage and Transcriptional Regulation of Murine Bcrp1.

Authors:  Karthika Natarajan; Yi Xie; Takeo Nakanishi; Rebecca S Moreci; Pancharatnam Jeyasuria; Arif Hussain; Douglas D Ross
Journal:  J Vis Exp       Date:  2016-05-27       Impact factor: 1.355

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.